Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

A new study looked at the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. At the end of the 72 ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.